This activity is expired and is no longer available for CME credit.


Key Considerations for Optimizing Neovascular AMD Treatment: Dosing Regimens and Residual Retinal Fluid

Author(s)/Faculty: Diana V. Do, MD; Nathan C. Steinle, MD
Release Date: 12/23/2020Expiration Date: 12/22/2021
Credit Type: CME / ABO MOCNumber of Credits: 0
Content Type: VideoProvider:
Visual acuity outcomes from real-world analysis of patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) therapies are often not comparable to the significant visual acuity gains reported from clinical trials. These discrepancies might come from undertreatment of disease or decreased patient adherence due to the high treatment burden. Another consideration is the emerging role of persistent retinal fluid on visual outcomes, and how this might influence treatment paradigms. Within the CME activity, experts in the field assess new therapeutic regimens that optimize the dosing, administration, and efficacy of anti-VEGF therapies in patients the nAMD, as well as examine how the persistence of retinal fluid may influence visual outcomes in these patients.